RJA
JAZZ icon

Raymond James & Associates’s Jazz Pharmaceuticals JAZZ Stock Holding History

Raymond James & Associates’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-11,900
Closed -$19K – 3521
2017
Q4 		$19K Sell
11,900
-600
-5% -$83.2K ﹤0.01% 3345
2017
Q3 		$48K Buy
12,500
+400
+3% +$60.5K ﹤0.01% 3243
2017
Q2 		$86K Buy
+12,100
New +$1.85M ﹤0.01% 3131

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Raymond James & Associates's JAZZ Position: Q3 2024 in Review

Raymond James & Associates increased its Jazz Pharmaceuticals (JAZZ) stake by 13% in Q3 2024, buying an estimated $690K and bringing the position to 53,611 shares worth $5.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1531.

Raymond James & Associates first reported a position in JAZZ in Q2 2013 and has held it in 36 quarters since. The position peaked at $9.46M in Q2 2021. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

  • Raymond James & Associates held 53,611 shares of Jazz Pharmaceuticals worth $5.97M as of Q3 2024.
  • Raymond James & Associates bought 6,293 Jazz Pharmaceuticals shares in Q3 2024, an estimated $690K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1531 holding.
  • Raymond James & Associates first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
  • Raymond James & Associates's Jazz Pharmaceuticals position peaked at $9.46M in Q2 2021.
  • 477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.